EPO announces intention to grant BMB an additional patent
The European patent office (EPO) has announced its intention to grant another patent for Biomedical Bonding AB. The patent is entitled “A composition comprising thiol, alkene and phosphonic acid containing compounds for use as a primer for adhesion improvement”.
“This patent further strengthens Biomedical Bonding’s Bonevolent™ patent portfolio with emphasis on novel primers and their use in bone fixation and restoration treatments. The Bonevolent™ technology is founded on resin-composites with increased biocompatibility, tissue-friendliness, and high mechanical strength” comments Evelina Mikaelson, CEO, Biomedical Bonding AB.
For more information, please contact:
CEO Biomedical Bonding AB
Phone: +46 (0)76 34 22 824
About Biomedical Bonding AB
Biomedical Bonding AB is a platform based Swedish MedTech company that develops cutting-edge medical adhesive fixators and novel surgical methodologies with focus on the ever-growing market of hard tissue restorations. The technological platform, Bonevolent™, is market disruptive and stands for a paradigm shift in personalized surgical interventions. BMB´s vision is to become the dominant global provider of unique adhesive products suited for fracture fixation and dental restoration market. BMB´s Bonevolent™ products are easy-to-use by clinicians, will increase patient safety, save costs and resources for health care and society as a whole. BMB is a privately held company headquartered in Stockholm, Sweden.